InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection ( ILIAD-7-US-I )

Exclusion Criteria

• •1. Pregnancy or breast feeding
• •2. ALT and/or AST \> 5 x ULN
• •3. Known, active auto-immune disease;
• •4. Ongoing cancer treatment with chemotherapy / immunotherapy or any cancer therapy within last 3 months and/or ongoing
• •5. Patients with past history of Solid Organ transplant
• •6. Active tuberculosis, uncontrolled active HBV or HCV infection, HIV with positive viral load
• •7. Hospitalized patients with refractory hypoxia, defined as inability to maintain saturation \>85% with maximal available therapy for \>6 hours
• •8. Patients receiving any agent with immune suppressive effects, other than steroids at dosages less than 300 mg/day equivalent hydrocortisone and/or anti-IL-6R treatments like Tocilizumab or Sarilumab or anti-IL-1 treatment like Anakinra which should preferably be minimized
• •9. Patients with baseline Rockwood Clinical Frailty Scale ≥ 6 at Hospital admission
• •10. Patients showing an increase of the NEWS2 score by more than 6 points during the screening/ baseline period (48 to 72 hrs prior to first administration)
• •11. Patients under guardianship